Gastroenterology and Hepatology

Episodes 1-12 of 12

• 

  RestartResume

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  RestartResume

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  MinuteCE®

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  MinuteCE®

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  RestartResume

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  MinuteCE®

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  RestartResume

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  MinuteCE®

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  MinuteCE®

  Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies

  1.25 credits 11 episodes

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 credits 11 episodes

• 

  RestartResume

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  RestartResume

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  MinuteCE®

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  MinuteCE®

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  RestartResume

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  MinuteCE®

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  RestartResume

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  MinuteCE®

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago

  RestartResume

  Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago

  MinuteCE®

  Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits